Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00051688

Enrollment

Unknown

Registered

2003-01-16

Start date

2003-06-30

Completion date

2004-08-31

Last updated

2006-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Brief summary

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Interventions

DRUGtezacitabine

DRUGoxaliplatin

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy. * Patients must have at least one measurable tumor. * Patients may not have received prior treatment with oxaliplatin.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026